Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... 6 The FDA has approved new technology that ... faster. The SonoCine Automated Whole-breast Ultrasound Method and is ... Arizona Breastnet, in Scottsdale. This unique technology is designed ... yearly mammography screening. Until now, ultrasound has only been ...
... , MARLTON, N.J., Dec. 4 Thermographic ... Center in Marlton, New Jersey continues to provide superior ... dental, TMJ and sinus regions to assist in the ... , Thermography utilizes infrared imaging cameras that "read" the ...
Cached Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Discover Health Through Awareness 2Discover Health Through Awareness 3
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... (April 16, 2014) A team that includes scientists from ... Science Center at San Antonio, Johns Hopkins University and St. ... a common fungus to infect the body. , The fungal ... and oral thrush, and is the most common fungal pathogen ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
(Date:4/14/2014)... Ford Hospital reached a medical milestone April 3, performing ... way to access the heart. , Henry Ford is ... unique procedure called transcaval valve replacement, which accesses the ... Michigan resident Viola Waller, 80, underwent Henry Ford,s first ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2
... Lomb is one of the leading company which manufactures contact ... serious eye infections in some users. // After ... inspect Bausch & Lomb facilities. There was extensive microbiological testing ... analyze the culprit behind the eye infection. Bausch & Lomb ...
... the wonder enzyme in sepsis increases the bodys vulnerability ... confers strong resistance to sepsis. // ,This ... humans. ,"The results of the study make ... elimination of bacterial pathogens, and that a deficiency allows ...
... it has been categorized in A,B and C. A biological ... call for special actions by the pubic health system. // ... at Rockefeller University which suggests that a newly discovered protein ... areas in which anthrax spores have been released. ...
... to the hospitals in the twin cities,following symtoms of cough, ... flu infection. // ,With this , the total ... ministry has confrimed that no H5N1 strain has been detected ... culled ever since the outbreak. ,The suspected bird ...
... behind the aggressive head and neck cancer was unveiled by ... // It is a highly malignant form of cancer ... triple interaction between CD44, hyaluronan (HA), and LARG. CD44 is ... a variety of cellular functions. Hyaluronan (HA) is a complex ...
... the more evident after this pathbreaking study. Overeating and ... children accoding to the study. // ,This study ... trend of childhood obesity, which is perhaps a reminder to ... advertisments targeting children. ,Nearly 5,407 students from 90 public ...
Cached Medicine News:Health News:Sepsis risk increased due to the absence of one key enzyme 2Health News:A Detail Analysis of Head and Neck Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: